Shane Fontenot
Optometrist · Jennings, LANPI 1164612529
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,250 of the $22,530 with a category attached, or 85.4%. Coopervision Inc. accounts for 90.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $8,680 and has fallen 56.4% since, to $3,782 in 2025. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $369.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$20K
- Optos, Inc.$834
- Glaukos Corporation$446
- Sun Pharmaceutical Industries Inc.$273
- Alcon$143
- Bausch & Lomb Americas Inc.$111
- plus $402 from 8 others
What the payments were for
- Speaking & faculty fees$19,25085%
- Food & beverage$2,94913%
- Gifts$190%
- Entertainment$3111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 22 | $20,320 |
| Optos, Inc. | 8 | $834 |
| Glaukos Corporation | 5 | $446 |
| Sun Pharmaceutical Industries Inc. | 4 | $273 |
| Alcon | 8 | $143 |
| Bausch & Lomb Americas Inc. | 1 | $111 |
| Johnson & Johnson Vision Care, Inc. | 3 | $93 |
| AbbVie(2 entities) | 3 | $86 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $59 |
| Harrow Eye, LLC | 1 | $46 |
| Oyster Point Pharma, Inc. | 2 | $41 |
| Maculogix, Inc. | 1 | $40 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biofinity Contact Lens$15,750
- Clariti Contact Lens$3,500
- PANORAMIC OPHTHALMOSCOPE$726
- MyDay Contact Lens$719
- OCT OPHTHALMOSCOPE$363
- NFC-700$363
- P200DTx$322
- P200T$322
- P200TE$322
- P200TxE$322
- CEQUA$250
- KXL System$223
- Photrexa$223
- iStent Trabecular Micro-Bypass System Model iS3$146
- MIEBO$111
- XIIDRA$111
How this compares
$22,530 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 36 | $22,802 |
| Cyclosporine | 11 | $6,520 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $5,835 |
| LumiganBimatoprost | 15 | $5,545 |
| Prednisolone Acetate | 107 | $2,834 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,444 |
| Latanoprost | 319 | $2,129 |
| Timolol Maleate | 60 | $762 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 41 | $506 |
| Azelastine Hcl | 18 | $501 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $232 |
| Brimonidine Tartrate | 13 | $79 |
| Cephalexin | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $86 | $34,18372 claims |
| AlconSimbrinza | $143 | $2,44412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Jennings
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
- Robert JanotSulphur$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.